הלוואות ואשראי לטווח ארוך של החברה: AbCellera (ABCL)

ABCL's price history shows long-term debt at 0.13. The high profitability of AI services is temporarily reduced by research and development costs, while profit growth is tied to patent royalties. Capitalization is based on fees collected from pharmaceutical companies for the use of microfluidic algorithms. Revenue is generated through entry fees, bonuses for successful testing, and future percentages from drug sales.

Investors must balance the growth potential of AbCellera Biologics (ABCL) with debt sustainability to avoid the risk of excessive financial leverage. An analysis of the company's long-term debt on the GURU.Markets platform displays obligations with maturities exceeding one year, allowing for an assessment of AbCellera Biologics' investment activity in developing its antibody discovery IT platform and its risk diversification through partnerships with pharma behemoths.